* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Human Immunoglobulin as a Treatment for West Nile Virus Infection
Survey
Document related concepts
Schistosomiasis wikipedia , lookup
Herpes simplex wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Oesophagostomum wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Neonatal infection wikipedia , lookup
Influenza A virus wikipedia , lookup
Orthohantavirus wikipedia , lookup
Ebola virus disease wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Hepatitis C wikipedia , lookup
Human cytomegalovirus wikipedia , lookup
Marburg virus disease wikipedia , lookup
Antiviral drug wikipedia , lookup
Herpes simplex virus wikipedia , lookup
Hepatitis B wikipedia , lookup
Henipavirus wikipedia , lookup
Transcript
E D I T O R I A L C O M M E N TA R Y Human Immunoglobulin as a Treatment for West Nile Virus Infection Amy Guillet Agrawal1 and Lyle R. Petersen2 1 Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland; 2Division of Vector-Borne Infectious Diseases, Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado (See the article by Ben-Nathan et al. on pages 5–12.) During the West Nile virus outbreak in Israel in 2000, a woman with chronic lymphocytic leukemia who was comatose as a result of West Nile virus encephalitis recovered after treatment with intravenous immunoglobulin (IVIG) [1]. Antibody titers against West Nile virus were 1:1600 in Israeli IVIG; in contrast, North American IVIG preparations had no detectable West Nile virus antibody [1, 2]. A second patient, a lung transplant recipient, also recovered from West Nile virus encephalitis after treatment with Israeli IVIG [3]. Six other subsequently treated patients have had variable outcomes: 2 improved, 2 had no improvement, and 2 eventually died [4] (C. Isada, oral communication; R. Babecoff, written communication). These anecdotal reports, although inconclusive, have stimulated interest in the use of passive immunization for treating severe West Nile virus disease. The article on the efficacy of human immunoglobulin in treating West Nile virus infection in mice by Ben-Nathan et al. [5] is provocative, in that it suggests that Received 12 May 2003; accepted 14 May 2003; electronically published 23 June 2003. Reprints or correspondence: Dr. Lyle R. Petersen, Div. of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, PO Box 2087 (Foothills Campus), Fort Collins, CO 80522 ([email protected]). The Journal of Infectious Diseases 2003;188:1–4 This article is in the public domain, and no copyright is claimed. 0022-1899/2003/18801-0001 IVIG might ameliorate or abort established West Nile virus infection. In the series of experiments described, BALB/c mice were infected intraperitoneally with either 20 or 200 times the LD50 (100 or 1000 pfu). They received 1 of 6 treatments: nonimmune mouse serum, immune mouse serum with ELISA titers against West Nile virus of 1:3200, Omrix IVIG with ELISA titers of 1:1600, IVIG from US donors with ELISA titers of 1: 10, pooled plasma from Israeli donors (titers not described but presumed to be less than concentrated immunoglobulin), or pooled plasma from US donors. In protection experiments in which the antibody-containing treatments were given shortly before and after infection, the results were unequivocal—any treatment containing specific antibody produced 100% survival, and treatments without specific anti–West Nile virus antibody provided no protection (100% mortality; table 1). In subsequent experiments, the infected mice were treated with 1–5 injections of specific anti–West Nile Virus antibody, with a clear dose- and time-dependent relationship to survival (table 1). Importantly, all treatments were started during the viremic phase, before virus entered the brain. It was established that virus entry into the brain occurred on day 3 after injection with the 1000-pfu inoculum and on days 6–8 after injection with the 100pfu inoculum in untreated West Nile virus–infected control mice. Finally, highdose antibody treatment administered 1 and 2 days or 2 and 3 days after injection with the 100-pfu inoculum afforded complete protection; however, antibody administered 3 and 4 days after infection yielded only 50% survival, although those mice that died survived longer than controls. Evidence suggests that West Nile virus may be more susceptible to antibody-mediated immunity than to cell-mediated immunity. Clearance of primarily neurotropic viruses is not dependent on cytolytic T cell activity, in contrast to nonneurotropic viruses [11, 12]. Neurons, as terminally differentiated cells, do not express major histocompatibility complex class I, which would subject them to lysis by CD8 T cells and nonreplacement [12]. Animal data support this concept. In the 1970s, Camenga et al. [6] challenged mice with West Nile virus, gave them cyclophosphamide 1 day later to suppress both the humoral and T cell–mediated arms of immunity, and then administered immune serum or immune syngeneic spleen cells at varying times (table 1). One injection of immune serum at day 5 or 6 resulted in 82% survival, and 1 injection at day 8 or 10 resulted in 22% survival, compared with 3% survival in controls. EDITORIAL COMMENTARY • JID 2003:188 (1 July) • 1 Table 1. Summary of published animal studies that used immunoglobulin for protection against or treatment of experimental flaviviral infection. Survival in indicated treatment group, % Source Flavivirus Animal(s) Ben-Nathan et al. [5] WNV BALB/c mice: 4 weeks old Camenga et al. [6] WNV BALB/c mice: 4–8 weeks old Diamond et al. [7] Tesh et al. [8] Mathews and Roehrig [9] WNV WNV SLEV mMT mice (B cell deficient) Golden hamsters: 10–11 weeks old BALB/c mice Kriel and Eibl [10] TBEV BALB/c mice NOTE. a b Day virus was found in brain b 3–8 6 4 ND 4 4 Time of a treatment Specific anti-WNV antibody Nonspecific antibody Untreated infected control ⫺1, 1, and 3 1 1 and 2 1, 2, and 3 1–5 3 and 4 1 or 2 5 or 6 8 or 10 ⫺1 and 1 ⫺1 1 4 1 3 100 64 75 92 100 50 94 82 22 100 100 100 30 190 25–30 0 ND ND ND ND ND 0 ND ND 0 ND ND ND ND ND 0 0 0 ND 0 0 3 ND ND ND ND 0 0 0 0 ND, not determined; SLEV, St. Louis encephalitis virus; TBEV, tickborne encephalitis virus; WNV, West Nile virus. Day(s) after infectious challenge on which treatment was administered. Virus found in brain on day 3 after challenge with 1000 pfu of WNV and on days 6–8 after challenge with 100 pfu of WNV. Notably, virus was detectable in the brain at day 6. Immune syngeneic spleen cells rescued 87% of mice at day 2 but only 13% at day 4; survival among controls was 12% [6]. Diamond et al. [7] have described the effects of immunoglobulin in several different mouse models of West Nile virus infection. In a B cell knockout model, a single plaque-forming unit of West Nile virus given by footpad inoculation constitutes the LD50. All mice given specific immunoglobulin 1 day before and 1 day after infectious challenge with a lethal inoculum of West Nile virus (100 pfu) survived, compared with none of the controls (table 1). In wild-type mice, immune serum produced results similar to those reported by Ben-Nathan et al. [5]; after inoculation with 100 pfu of West Nile virus, immune serum produced 80% survival if administered at 24 h and 50% survival if administered at 4 days, versus 20% survival in control animals (M. S. Diamond, unpublished data). Xiao et al. [13] established a model of West Nile virus encephalitis in Syrian golden hamsters. After intraperitoneal in- oculation, moderate viremia was detected for the first 5 days after infection. Natural antibody levels increased by day 5, and viremia became undetectable by day 7. By day 5, neuronal degeneration was evident, and by days 7–8, degeneration had localized to the deeper layers of the cerebral cortex, Purkinje cells in the cerebellum, and the brain stem. Death occurred in ∼50%–70% of the infected animals between 7 and 14 days after infection. In another study using the same model, hamsters (18 weeks old) treated with exogenous immune serum 24 h before infection were completely protected from viremia and death (table 1) [8]. However, if antibody administration was delayed 48 h after infection, no survival effect was seen (R. B. Tesh, unpublished data). Finally, in recent experiments, golden hamsters and BALB/c mice were given Israeli IVIG, IVIG from US donors, or saline on day 1 and 2 after intraperitoneal injection with West Nile virus. Older hamsters (18 weeks old) showed no survival benefit with IVIG, but younger hamsters (4–5 weeks old) had 100% survival when Israeli IVIG was used and 20% survival 2 • JID 2003:188 (1 July) • EDITORIAL COMMENTARY when US IVIG was used. Among BALB/ c mice, 90% of those given Israeli IVIG survived, compared with 10% of those given US IVIG (J. D. Morrey, unpublished data). The results of Ben-Nathan et al. [5] and other groups showing clear-cut protection by IVIG when animals are treated before or shortly after infectious challenge with West Nile virus provide support for the potential usefulness of IVIG in the treatment of acute West Nile virus infection in humans. Passive immunization of humans for treatment of other viral infections has precedent. Examples include parvovirus in patients with human immunodeficiency virus [14]; chronic echovirus meningoencephalitis in children [15–17]; disseminated vaccinia infection [18]; Junin virus, the agent of Argentine hemorrhagic fever [19]; and cytomegalovirus pneumonitis in bone marrow transplant recipients [20]. A critical question is whether IVIG is effective when cerebral infection has been established. Successful treatment of animals challenged with St. Louis encephalitis and tickborne encephalitis viruses, flaviviruses related to West Nile virus, was pos- sible several days after infection; however, the therapeutic effect decreased rapidly once virus was found in brain (table 1) [9, 10]. Other neurotropic viruses are amenable to treatment with antibody [21–23]. Studies by Griffin and coworkers [12, 21] indicated an important role for antibody in the clearance of neuroadapted Sindbis virus after well-established brain infection. Virgin and Tyler and their associates [22, 23] successfully treated reovirus brain infection with intraperitoneally administered antibody up to 7 days after infectious challenge. In the preantibiotic era, horse serum treatment for meningitis caused by Neisseria meningitidis significantly reduced mortality [24]. The efficacy of antibody therapy for cerebral infection depends on passage of IgG through the blood-brain barrier. Studies in humans without inflamed meninges show that IgG enters at very low levels [25]. Entry is enhanced, however, once inflammation is present. In a study of patients who developed aseptic meningitis as a complication of highdose IVIG therapy for autoimmune disease, IgG levels of 1.5–7 times the upper limit of normal were seen in cerebrospinal fluid [26]. There are several limitations to the study by Ben-Nathan et al. [5]. One concern is that success was shown in animal models when antibody was given during the viremic phase; however, nearly all patients with West Nile virus infection are no longer viremic when they present, and most have already developed IgM antibody [27, 28]. Another limitation was that even the lower infecting dose used by BenNathan et al. [5] produced 100% mortality in untreated mice. But the infectious inoculum from a mosquito bite is far less, and most persons infected remain asymptomatic. It would be of interest to see how long after an infectious inoculum is injected IVIG can produce a survival benefit, particularly when the inoculum is low. Another potential limitation was the choice of infecting strain. Whereas other recent work investigating the efficacy of antibody against West Nile virus in animal models has used contemporary strains from the US outbreak [7, 8], Ben-Nathan et al. [5] used a 1954 strain. Although the establishment of an LD50 still ensures adequate virulence, differences in strain may produce different responses to treatment. In work screening other compounds in vitro, Morrey et al. [29] found an up to 30-fold difference in EC50 (the amount of a compound required to abrogate 50% of the cytopathic effect produced by a virus) for some compounds when they used a recent New York strain, compared with the 1937 Uganda strain of West Nile virus. Finally, the efficacy of antibody therapy demonstrated in animal models may not translate directly to humans. As an example from the preantibiotic era, the mouse model of pneumococcal infection showed that treatment with horse serum was only effective when given within 12 h, but when this therapy was transferred to humans for this otherwise untreatable disease, it was very effective when given within 4 days [24]. Current candidate agents for treatment of severe West Nile virus disease include ribavirin, interferon (IFN)–a2b, and hightiter anti–West Nile virus immunoglobulin. Ribavirin has some activity at very high doses in vitro [29, 30]. Patients who received ribavirin during the 2000 West Nile virus outbreak in Israel had increased mortality; however, this was likely due to the fact that ribavirin was administered to sicker patients [31]. If the high levels required for any antiviral activity in vitro are extrapolated to levels achievable in human cerebrospinal fluid, extraordinarily high intravenous doses (on the order of 4 g/ day) would be required achieve levels between the in vitro EC50 and the EC90 for oligodendroglial cells [30]. Such doses are associated with significant, although reversible, hemolytic anemia. IFN-a2b is active in vitro against West Nile virus [32] but has not been tested in an animal model of West Nile virus. Its in vitro activity and broad immunostimulatory activity [33] have prompted several clinical trials involving flaviviral diseases. In an outbreak of St. Louis encephalitis in Louisiana, IFN-a2b was used expediently in a nonrandomized open-label fashion. The first 17 patients in the outbreak were treated with supportive care only; the next 15 patients were treated with IFN-a2b [34]. Neither group experienced mortality. Although the mean neurological score improved in the treated group and worsened in the untreated group by week 3, these results must be interpreted with considerable caution, because the study was not randomized, there was no placebo group, and the scoring scale was applied in an unblinded fashion [34]. An open-label study examining the effect of IFN-a2b versus supportive care for West Nile virus infection is ongoing (J. J. Rahal, written communication). A large, double-blind, placebo-controlled study failed to find a difference in mortality or functional outcome resulting from the use of IFN-a2b for treatment of Japanese encephalitis, a related flavivirus, in Vietnam [35]. Although studies such as that by BenNathan et al. [5] suggest that flaviviral infections are at least partially treatable with passive immunity, if antibody is going to work at all, it must be administered early. The side-effect profile of IVIG compares favorably with that of the other 2 main candidate therapies (ribavirin and IFN), and, without a human trial, there will be no way to know whether the results in animals will translate to a significant benefit in humans. The high mortality seen among persons with West Nile virus encephalitis and the long-term morbidity among survivors [36, 37] provide impetus for such a trial. Patients with established neurological disease or who are at high risk for progression to severe disease but who have not yet developed encephalomyelitis would be candidates for any effective therapy. Risk factors for progression of disease are advanced age or immunosuppression, although the type of immunosuppression is not yet well defined [31, 36, 38]. If IVIG or any agent is found to be effective, rapid diagnosis will become far more important to identify potentially treatable patients EDITORIAL COMMENTARY • JID 2003:188 (1 July) • 3 early in the course of disease. The unpredictability of flaviviral outbreaks other than Japanese encephalitis complicates planning of human clinical trials; if the high incidence of severe West Nile virus illness observed in 2002 in North America is repeated in coming years, there may exist a unique opportunity to determine whether early treatment of West Nile virus infection with specific antibody is beneficial. 10. 11. 12. 13. References 1. Shimoni Z, Niven MJ, Pitlick S, Bulvik S. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 2001; 7:759. 2. Feinstein S, Akov Y, Lachmi BE, Lehrer S, Rannon L, Katz D. Determination of human IgG and IgM class antibodies to West Nile virus by enzyme linked immunosorbent assay (ELISA). J Med Virol 1985; 17:63–72. 3. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 2002; 4:160–2. 4. Haley M, Retter A, Fowler D, Gea-Banacloche J, O’Grady NP. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis (in press). 5. Ben-Nathan D, Lustig S, Tam G, Robinzon S, Segal S, Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003; 188:5–12 (in this issue). 6. Camenga DL, Nathanson N, Cole GA. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 1974; 130:634–41. 7. Diamond MS, Shrestha B, Marri A, Mahan D, Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578–86. 8. Tesh RB, Arroyo J, Travassos da Rosa AP, Guzman H, Xiao SY, Monath TP. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002; 8: 1392–7. 9. Mathews JH, Roehrig JT. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint 14. 15. 16. 17. 18. 19. 20. 21. 22. Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 1984; 132:1533–7. Kreil TR, Eibl MM. Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997; 71:2921–7. Griffin DE, Ubol S, Despres P, Kimura T, Byrnes A. Role of antibodies in controlling alphavirus infection of neurons. Curr Top Microbiol Immunol 2001; 260:191–200. Levine B, Hardwick JM, Trapp BD, Crawford TO, Bollinger RC, Griffin DE. Antibody-mediated clearance of alphavirus infection from neurons. Science 1991; 254:856–60. Xiao SY, Guzman H, Zhang H, Travassos da Rosa AP, Tesh RB. West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis. Emerg Infect Dis 2001; 7:714–21. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med 1990; 113:926–33. Dwyer JM, Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. Pediatr Infect Dis J 1988; 7:S30–3. Erlendsson K, Swartz T, Dwyer JM. Successful reversal of echovirus encephalitis in X-linked hypogammaglobulinemia by intraventricular administration of immunoglobulin. N Engl J Med 1985; 312:351–3. Kondoh H, Kobayashi K, Sugio Y, Hayashi T. Successful treatment of echovirus meningoencephalitis in sex-linked agammaglobulinaemia by intrathecal and intravenous injection of high titre gammaglobulin. Eur J Pediatr 1987; 146:610–2. Sharp JC, Fletcher WB. Experience of antivaccinia immunoglobulin in the United Kingdom. Lancet 1973; 1:656–9. Maiztegui JI, Fernandez NJ, de Damilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 1979; 2:1216–7. Emanuel D, Cunningham I, Jules-Elysee K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and highdose intravenous immune globulin. Ann Intern Med 1988; 109:777–82. Stanley J, Cooper SJ, Griffin DE. Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice. J Virol 1986; 58:107–15. Virgin HW 4th, Bassel-Duby R, Fields BN, Tyler KL. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol 1988; 62:4594–604. 4 • JID 2003:188 (1 July) • EDITORIAL COMMENTARY 23. Tyler KL, Virgin HW 4th, Bassel-Duby R, Fields BN. Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system. J Exp Med 1989; 170:887–900. 24. Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38:1695–702. 25. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994; 57:21–5. 26. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994; 121: 259–62. 27. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2:519–29. 28. Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med 2002; 137:173–9. 29. Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res 2002; 55:107–16. 30. Jordan I, Briese T, Fischer N, Lau JY, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182:1214–7. 31. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675–8. 32. Anderson JF, Rahal JJ. Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis 2002; 8:107–8. 33. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14:778–809. 34. Rahal JJ. Effect of interferon alpha 2b therapy on St. Louis virus meningoencephalitis: clinical and laboratory results. Bethesda, MD: National Institutes of Health, Workshop on Therapeutics for West Nile Virus Infection, 2002. 35. Solomon T, Dung NM, Wills B, et al. Interferon alpha-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet 2003; 361:821–6. 36. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001; 344:1807–14. 37. West Nile virus surveillance and control: an update for healthcare providers in New York City. New York City Department of Health. City Health Information 2001; 20:1–6. 38. Iwamoto M, Jernigan DB, Guasch A, et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348:2196–203.